Stay updated with breaking news from Entrypoint Capital. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) have received a consensus rating of “Buy” from the nine ratings firms that are covering the company, MarketBeat Ratings reports. Eight analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price […]
Primoris Services Co. (NASDAQ:PRIM – Get Free Report) Director John P. Schauerman sold 10,000 shares of the company’s stock in a transaction dated Wednesday, May 22nd. The stock was sold at an average price of $52.91, for a total transaction of $529,100.00. Following the completion of the sale, the director now directly owns 192,281 shares […]
Shares of Brookline Bancorp, Inc. (NASDAQ:BRKL – Get Free Report) have been given an average recommendation of “Moderate Buy” by the four brokerages that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1-year […]
Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Free Report) has been given a consensus rating of “Moderate Buy” by the thirteen research firms that are presently covering the stock, Marketbeat.com reports. Five analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12-month price objective […]
Wedbush restated their outperform rating on shares of Monte Rosa Therapeutics (NASDAQ:GLUE – Free Report) in a report issued on Wednesday morning, Benzinga reports. The firm currently has a $11.00 price objective on the stock. Wedbush also issued estimates for Monte Rosa Therapeutics’ Q2 2024 earnings at ($0.37) EPS, Q3 2024 earnings at ($0.34) EPS, […]